Devicor touts FDA nod for its next-gen breast biopsy system
The FDA approves Devicor's Mammotome revolve device, a less invasive dual vacuum-assisted biopsy system for sampling breast tissue.
Cincinnati, Ohio-based Devicor landed FDA approval for its Mammotome revolve biopsy system, a next-generation biopsy system designed to provide high quality tissue specimens while improving the efficiency of pre-biopsy planning time.
The Mammotome system features specimen management for collecting and organizing high quality individual tissue samples in numbered, as well as specimen radiograph and pathology-ready chambers to preserve tissue integrity. The less invasive DualVac vacuum technology also helps clinicians secure larger contiguous tissue samples, according to the press release.